Shaalan Beg MD MBA FASCO

Reimagining cancer clinical trials.
Foodie, family guy, digital health.
FCOI:

[Richard Y. Ebright, MD, PhD @RYEbright]

Last year, we reported that KRAS+PRMT5 is synergistic in MTAP-null PDAC (https://t.co/mIc6hkbMpL). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.

RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD

[Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1]

The Onco #HotTakes series begins! From #OnlyOncologistsintheBuilding launched from discussion at #ASCO26.

All episodes - full episodes and shorts - available on our @YouTube channel:

https://t.co/n7NMcvyOtS
with @ShaalanBeg & @ShrutiPatelMD

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

Launching our #hottakes series w the prolific @DrArturoAI

#onlyoncologistsinthebuilding
#asco26

👇🏻

https://t.co/1p9LrY0B3B

[Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1]

@JasmineKambojMD @OncBrothers @ShaalanBeg @ShrutiPatelMD @aakonc @realbowtiedoc @TimothyJBrownMD @PanCAN @letswinpc @NiuSanford @VivekSubbiah Many thanks @JasmineKambojMD !! @ShaalanBeg @ShrutiPatelMD https://t.co/n7NMcvyOtS

[Nurullah İlhan,MD @drnurullahilhan]

Pancreatic cancer is finally seeing real hope with KRAS inhibitors, neoantigen vaccines, and AI-powered early detection. These advances are game-changing.
Grateful to the entire team for breaking it down so clearly.
@realbowtiedoc @cancerassassin1 @ShaalanBeg @ShrutiPatelMD
#PancreaticCancer #Oncology #OncTwitter

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

@chadinabhan @OncBrothers @ShrutiPatelMD @cancerassassin1 @aakonc @realbowtiedoc @TimothyJBrownMD @PanCAN @letswinpc @NiuSanford @VivekSubbiah You know you shouldn't eat so much baklava at your age...

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

Pancreatic cancer will look very different in 5 years

✅ KRAS is no longer "undruggable"
✅ Neoantigen vaccines may stop recurrence
✅ AI can identify 'occult' tumors from routine scans

We tackle these stories in our new episode!

#onlyoncologistsinthebuilding

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

@chadinabhan @OncBrothers @ShrutiPatelMD @cancerassassin1 @aakonc @realbowtiedoc @TimothyJBrownMD @PanCAN @letswinpc @NiuSanford @VivekSubbiah Never

[David S. Hong MD @DavidHongMD]

Speak it!

[Julie Gralow @jrgralow]

Powerful and poignant #asco2026 President’s Address by Eric Small: “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide” @asco https://t.co/zKdgDrCZ1N

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

@OncBrothers @ShrutiPatelMD @cancerassassin1 @aakonc @realbowtiedoc @TimothyJBrownMD @PanCAN @letswinpc @NiuSanford @VivekSubbiah 🙏🏻

[Oncology Brothers @OncBrothers]

@ShaalanBeg @ShrutiPatelMD @cancerassassin1 @aakonc @realbowtiedoc @TimothyJBrownMD @PanCAN @letswinpc @NiuSanford @VivekSubbiah There are so many podcasts so why tune in to this one?

1. If you are loking for broad coverage of topics in medicine…

2. Looking for multiple expert perspectives….

3. Looking for 3 hosts with great chemistry…

4. Want to learn something new….

Then this is it!

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

@thoughtson_tech Agree that science takes time, and we can't afford to miss efficacy signals. I believe the study was overpowered and w the effect size they were observing, maybe they did not need 500 patients.

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

Imagine this:

If CROs and academic centers would allow clinical trials activation and enrollment in the US to be modernized, the KRAS plenary would have been presented in #asco25 and we would have three more RAS trial readouts by today.

[Julie Gralow @jrgralow]

Accelerating time to trial activation to answer important clinical questions and improve standard of care to benefit patients more quickly - @AACI_Cancer - @asco stakeholders meeting with @FDAOncology @NCIDirector and many more! Lots of interest, time to turn that into action!

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

@BlayneyDouglas Sadly it is not IRB approvals anymore @BlayneyDouglas

NCI sponsored studies use central IRB, pre-approved budget, no contract and they still take 4 months to activate.

Hospital and ancillary service reviews need to be simplified

[DrDoug @BlayneyDouglas]

Agree with Dr. Beg here. Trial activation is too slow and too selective. There is also patient harm from cumulative addition of each step added with the intent to protect patients and investigators. Why not one central, responsive IRB?

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

We are excited to launch our new episode on @YouTube

Please give it a listen!

https://t.co/SjyUf8RUEE

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

Listen to our full episode on YouTube where we tackle these advances and summarize what it is that you need to know
#onlyoncologistsinthebuilding

https://t.co/rvWEIQ3y8F

[Santhosh Ambika @RenoHemonc]

@ShaalanBeg This tweet was from 4 years ago! So many patient years wasted due to bureaucratic delays in trial enrollment.

[Steve Lee @steveleeyc]

EAP needs improvement. @kpnorcal committed 4 trials/pharmacy staff for 3+ wks to get this rolling. Hard to do, even for resource-pinched academic centers, let alone community practice. Every week matters in cancers like #pancreaticcancer